Talbutal
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
(RS)-5-allyl-5-sec-butylpyrimidine-2,4,6(1H,3H,5H)-trione
|
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 115-44-6  |
| ATC code | N05CA07 (WHO) |
| PubChem | CID 8275 |
| DrugBank | DB00306 |
| ChemSpider | 7976 |
| UNII | 4YIR8202AX |
| ChEMBL | CHEMBL1200802  |
| Synonyms | 5-(1-methylpropyl)-5-(2-propenyl)-2,4,6(1H,3H,5H)-pyrimidinetrione |
| Chemical data | |
| Formula | C11H16N2O3 |
| Molar mass | 224.256 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
| (what is this?) (verify) |
|
Talbutal (Lotusate) is a barbiturate with a short to intermediate duration of action. It is a structural isomer of butalbital. Talbutal is a schedule III drug in the U.S.
Pharmacology[edit]
Talbutal is a short to intermediate-acting barbiturate. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.[1]
Mechanism of action[edit]
Talbutal binds at a distinct binding site associated with a Cl− ionopore at the GABAA receptor, increasing the duration of time for which the Cl− ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Toxicity[edit]
Symptoms of acute barbiturate poisoning include drowsiness, confusion, coma, respiratory depression, hypotension,[1] and shock.
References[edit]
 |
This article needs additional citations for verification. (December 2009) (Learn how and when to remove this template message) |
- ^ a b Mutschler, Ernst; Schäfer-Korting, Monika (2001). Arzneimittelwirkungen (in German) (8 ed.). Stuttgart: Wissenschaftliche Verlagsgesellschaft. pp. 280ff. ISBN 3-8047-1763-2.
 |
This sedative-related article is a stub. You can help Wikipedia by expanding it. |
